Stenzl, A., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Azad, A. A., … Armstrong, A. J. (2019). ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups. In ANNALS OF ONCOLOGY (Vol. 30, pp. 332-+). Barcelona, SPAIN: OXFORD UNIV PRESS.

Stenzl, A., R. Z. Szmulewitz, D. P. Petrylak, J. Holzbeierlein, A. Villers, A. A. Azad, A. Alcaraz, et al. “ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups.” In ANNALS OF ONCOLOGY, 30:332-+. OXFORD UNIV PRESS, 2019.

Stenzl A, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad AA, et al. ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups. In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2019. p. 332-+.

Stenzl, A., et al. “ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups.” ANNALS OF ONCOLOGY, vol. 30, OXFORD UNIV PRESS, 2019, pp. 332-+.

Stenzl A, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad AA, Alcaraz A, Alekseev BY, Iguchi T, Shore ND, Rosbrook B, Baron B, Haas GP, Morlock R, Ramaswamy K, Armstrong AJ. ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups. ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2019. p. 332-+.